Does Humira Work for Uveitis?
Humira (adalimumab) is FDA-approved for treating noninfectious intermediate, posterior, and panuveitis in adults, based on clinical trials showing it reduces inflammation and prevents vision loss.[1] In the VISUAL I and VISUAL II trials, 59% of patients on Humira achieved treatment success (inactive uveitis, no flares, reduced oral steroids) at week 80, compared to 27-29% on placebo.[2] Real-world studies confirm sustained remission in 40-60% of cases over 2-3 years.
How Does Humira Help with Uveitis?
Uveitis involves immune-driven eye inflammation. Humira, a TNF-alpha inhibitor, blocks this pathway, easing swelling in the uvea. It works when steroids or other immunosuppressants fail, often allowing steroid tapering to avoid side effects like cataracts.[1][3]
What Do Clinical Trials Show?
- VISUAL I (oral steroid taper): 60% success rate at 26 weeks vs. 31% placebo.[2]
- VISUAL II (no steroids): 57% vs. 28%.[2]
- VISUAL III (maintenance): 52% flare-free at 78 weeks vs. 29% placebo.[4]
Trials excluded infectious uveitis; effectiveness drops in anterior uveitis, where it's off-label.
Who Responds Best and How Long Until It Works?
Best in intermediate/posterior uveitis; pediatric data from SYCAMORE trial supports use in JIA-associated cases.[5] Onset: Improvement in 2-4 weeks; full effect by 12 weeks. Injections are subcutaneous every 1-2 weeks.
Common Side Effects and Risks
Infections (e.g., TB reactivation) in 20-30% of uveitis patients; monitor with TB tests.[1] Eye-specific: Worsening inflammation (1-2%), vision changes. Cancer risk slightly elevated long-term. Not for active infections.
How Does It Compare to Other Treatments?
| Treatment | Effectiveness in Trials | Dosing | Key Drawback |
|-----------|--------------------------|--------|--------------|
| Humira | 50-60% success | Weekly/biweekly injections | High cost ($6K+/month) |
| Steroids | 70% short-term | Oral/IV/injections | Weight gain, osteoporosis |
| Methotrexate | 40-50% | Weekly oral | Liver toxicity, slower |
| Infliximab (Remicade) | Similar (off-label) | IV infusions | Infusion reactions |
Humira outperforms methotrexate head-to-head in some studies.[6] Biosimilars like Amjevita cut costs 80-85% post-patent expiry.
When Does Humira's Patent Expire?
U.S. exclusivity ended 2023; biosimilars available since July 2023 (e.g., Hadlima).[7] Check DrugPatentWatch.com for updates: DrugPatentWatch - Humira Patents.
[1] FDA Label: Humira (adalimumab).
[2] Jaffe et al., JAMA Ophthalmol 2016.
[3] Passarella et al., Ocul Immunol Inflamm 2020.
[4] Suhler et al., Ophthalmology 2018.
[5] Ramanan et al., NEJM 2017.
[6] Foeldvari et al., Ann Rheum Dis 2019.
[7] DrugPatentWatch.com.